Summit Therapeutics Inc. (SMMT) — SEC Filings
Summit Therapeutics Inc. (SMMT) — 40 SEC filings. Latest: 8-K (Nov 7, 2025). Includes 29 8-K, 6 10-Q, 2 DEF 14A.
View Summit Therapeutics Inc. on SEC EDGAR
Overview
Summit Therapeutics Inc. (SMMT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 7, 2025: Summit Therapeutics Inc. filed an 8-K on November 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events or financial figures within the provided text.
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bearish, 39 neutral. The dominant filing sentiment for Summit Therapeutics Inc. is neutral.
Filing Type Overview
Summit Therapeutics Inc. (SMMT) has filed 29 8-K, 6 10-Q, 2 DEF 14A, 1 SC 13D/A, 1 DEFA14A, 1 10-K with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of SMMT's 35 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $ (860.4M) |
| EPS | $ (1.16) |
| Debt-to-Equity | N/A |
| Cash Position | $ 238.6M |
| Operating Margin | N/A |
| Total Assets | $ 261.7M |
| Total Debt | N/A |
Key Executives
- Duggan
- Zanganeh
- Robert W. Duggan
- Adam W. Finerman, Esq.
- Dr. Jonathan Edward
- Dr. Kevin J. Lee
Industry Context
Summit Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of novel therapies. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Companies like Summit rely heavily on R&D investment and often require substantial external financing to advance their pipelines through clinical trials and towards commercialization.
Top Tags
8-k (7) · sec-filing (7) · material-agreement (5) · corporate-governance (5) · 10-Q (4) · regulatory-filing (3) · filing (3) · financials (3) · executive-compensation (3) · 8-K (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $860.4M | Increased from $160.1M in 2024 for the nine months ended September 30, 2025, indicating a significant increase in operational losses. |
| Research and Development Expenses | $390.4M | Increased from $99.4M in 2024 for the nine months ended September 30, 2025, reflecting substantial investment in ivonescimab. |
| General and Administrative Expenses | $479.1M | Increased from $46.0M in 2024 for the nine months ended September 30, 2025, contributing significantly to the net loss. |
| Cash and Cash Equivalents | $238.6M | As of September 30, 2025, insufficient to fund operations for at least one year, highlighting liquidity concerns. |
| Accumulated Deficit | $2.07B | As of September 30, 2025, demonstrating a history of significant losses. |
| Common Shares Outstanding | 744.4M | As of October 14, 2025, indicating potential for further dilution with future capital raises. |
| Net Cash Used in Operating Activities | $221.0M | For the nine months ended September 30, 2025, a substantial increase from $93.4M in 2024, showing accelerated cash burn. |
| Proceeds from At-the-Market Offering | $31.8M | For the nine months ended September 30, 2025, a source of capital but insufficient to cover the burn rate. |
| Commission File Number | 001-36866 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 37-1979717 | Company's tax identification number. |
| SEC File Number | 001-36866 | Identifies the company's filing with the SEC. |
| Reporting Period End Date | 2025-03-31 | Marks the end of the financial quarter being reported. |
| Filing Date | 2025-05-01 | Indicates when the report was officially submitted to the SEC. |
| End of Reporting Period | 2024-09-30 | The 10-Q covers financial data up to this date. |
| Q3 2024 Period | 2024-07-01 to 2024-09-30 | Specific financial activities related to common stock and paid-in capital occurred during this quarter. |
Forward-Looking Statements
- {"claim":"Summit Therapeutics may issue a press release or further disclosure explaining the strategic rationale behind the headquarters relocation.","entity":"Summit Therapeutics Inc.","targetDate":"Q1 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Summit Therapeutics Inc. (SMMT)?
Summit Therapeutics Inc. has 40 recent SEC filings from Jan 2024 to Nov 2025, including 29 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SMMT filings?
Across 40 filings, the sentiment breakdown is: 1 bearish, 39 neutral. The dominant sentiment is neutral.
Where can I find Summit Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Summit Therapeutics Inc. (SMMT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Summit Therapeutics Inc.?
Key financial highlights from Summit Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SMMT?
The investment thesis for SMMT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Summit Therapeutics Inc.?
Key executives identified across Summit Therapeutics Inc.'s filings include Duggan, Zanganeh, Robert W. Duggan, Adam W. Finerman, Esq., Dr. Jonathan Edward and 1 others.
What are the main risk factors for Summit Therapeutics Inc. stock?
Of SMMT's 35 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Summit Therapeutics Inc.?
Recent forward-looking statements from Summit Therapeutics Inc. include guidance on {"claim":"Summit Therapeutics may issue a press release or further disclosure explaining the strategic rationale behind .